Future prospects for new vaccines against sexually transmitted infections

Current Opinion in Infectious Diseases

Volumn 30, Issue 1, 2017, Pages 77-86

  Gottlieb, Sami L ^a   Johnston, Christine ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Roadmap; Sexually transmitted infection vaccine development; Sexually transmitted infections; Vaccines

Indexed keywords

CHLAMYDIA TRACHOMATIS VACCINE; HERPES SIMPLEX VACCINE; NEISSERIA GONORRHOEAE VACCINE; SUBUNIT VACCINE; TREPONEMA PALLIDUM VACCINE; UNCLASSIFIED DRUG; VACCINE; BACTERIAL VACCINE; VIRUS VACCINE;

CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; GONORRHEA; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; NONHUMAN; REPRODUCTIVE HEALTH; REVIEW; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; VIRUS SHEDDING; IMMUNOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); TREPONEMA PALLIDUM;

BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; GONORRHEA; HERPESVIRUS 2, HUMAN; HUMANS; SEXUALLY TRANSMITTED DISEASES; SYPHILIS; TREPONEMA PALLIDUM; VIRAL VACCINES;

EID: 85002486892     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000343     Document Type: Review

References (84)

1. Meheus A, Spier RE. Vaccines for sexually transmitted diseases: proceedings of the conference 'Vaccines for Sexually Transmitted diseases', Oxford, UK 5-7 April 1989. London: Butterworths; 1989; 315 pp.
2. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-1651.
3. World Health Organization. Progress towards global immunization goals - 2015: Abstract: presentation of key indicators. 2016. http://www.who.int/immunization/monitoring-surveillance/en/. [Accessed 22 November 2016]
4. Garland SM, Kjaer SK, Munoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis 2016; 63:519-527.
5. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.NEngl J Med 2015; 372:711-723.
6. GLOBOCAN: International Agency for Research on Cancer. Cervical cancer: estimated incidence, mortality and prevalence worldwide in 2012. 2012. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. [Accessed 22 November 2016]
7. Gottlieb SL, Low N, Newman LM, et al. Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. Vaccine 2014; 32:1527-1535.
8. Scott HM, Klausner JD. Sexually transmitted infections and pre-exposure prophylaxis: challenges and opportunities among men who have sex with men in the US. AIDS Res Ther 2016; 13:5.
9. Kirkcaldy RD, HookEW3rd, Soge OO, et al. Trends in Neisseria gonorrhoeae susceptibility to cephalosporins in the United States, 2006-2014. JAMA 2015; 314:1869-1871.
10. Looker KJ, Magaret AS, Turner KM, et al. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One 2015; 10:e114989.
11. Newman L, Rowley J, Vander Hoorn S, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One 2015; 10:e0143304.
12. Wijesooriya NS, Rochat RW, Kamb ML, et al. Global burden of maternal and congenital syphilis in 2008 and 2012: a health systems modelling study. Lancet Glob Health 2016; 4:e525-e533.
13. Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. N Engl J Med 2015; 372:2039-2048.
14. Westrom L, Joesoef R, Reynolds G, et al. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992; 19:185-192.
15. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and metaanalysis of longitudinal studies. AIDS 2006; 20:73-83.
16. Kirkcaldy RD, Bolan GA, Wasserheit JN. Cephalosporin-resistant gonorrhea in North America. JAMA 2013; 309:185-187.
17. Sexually transmitted infections: vaccine development for global health. Vaccine 2014; 32:1523-1640.
18. Global Vaccine Action Plan. Decade of vaccine collaboration. Vaccine 2013; 31 (Suppl 2):B5-B31.
19. United Nations. Global strategy for women's, children's and adolescents health 2016-2030. Every Woman Every Child; 2015. http://globalstrategy.everywomaneverychild.org/. [Accessed 22 November 2016]
20. Broutet N, Fruth U, Deal C, et al. Vaccines against sexually transmitted infections: the way forward. Vaccine 2014; 32:1630-1637.
21. Gottlieb SL, Deal CD, Giersing B, et al. The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps. Vaccine 2016; 34:2939-2947.
22. Johnston C, Gottlieb SL, Wald A. Status of vaccine research and development of vaccines for herpes simplex virus. Vaccine 2016; 34:2948-2952.
23. Statens Serum Institut. Safety of chlamydia vaccine CTH522 in healthy women aged 18 to 45 years. https://clinicaltrials.gov/ct2/show/NCT02787109. 2016. [Accessed 22 November 2016]
24. Smith J, Garber GE. Current status and prospects for development of a vaccine against Trichomonas vaginalis infections. Vaccine 2014; 32:1588-1594.
25. Looker KJ, Magaret AS, May MT, et al. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PLoS One 2015; 10:e0140765.
26. Masese L, Baeten JM, Richardson BA, et al. Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. AIDS 2015; 29:1077-1085.
27. Cairns TM, Huang Z-Y, Gallagher JR, et al. Patient-specific neutralizing antibody responses to herpes simplex virus are attributed to epitopes on gD, gB, or both and can be type specific. J Virol 2015; 89:9213-9231.
28. Zhu J, Peng T, Johnston C, et al. Immune surveillance by CD8aa- skinresident T cells in human herpes virus infection. Nature 2013; 497:494-497.
29. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012; 366:34-43.
30. Belshe RB, Heineman TC, Bernstein DI, et al. Correlate of immune protection against HSV-1 genital disease in vaccinated women. J Infect Dis 2014; 209:828-836.
31. Wald A, Warren T, Fife KH, et al. Therapeutic HSV-2 vaccine (GEN-003) results in durable reduction in genital lesions at 1 year. Abstract presented at: ID Week. Philadelphia, PA; 2014.
32. Flechtner JB, Long D, Larson S, et al. Immune responses elicited by the GEN- 003 candidate HSV-2 therapeutic vaccine in a randomized controlled doseranging phase 1/2a trial. Vaccine 2016; 34:5314-5320.
33. Mammen MP. Therapeutic DNA vaccine for genital herpes. Abstract presented at: ASM/ICAAC 2016. Boston, MA; 2016.
34. Dutton JL, Woo WP, Chandra J, et al. An escalating dose study to assess the safety, tolerability and immunogenicity of a herpes simplex virus DNA vaccine, COR-1. Hum Vaccin Immunother 2016. [Epub ahead of print]
35. Bernard MC, Barban V, Pradezynski F, et al. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs. PLoS One 2015; 10:e0121518.
36. Jing L, Laing KJ, Dong L, et al. Extensive CD4 and CD8 T cell cross-reactivity between alphaherpesviruses. J Immunol 2016; 196:2205-2218.
37. Newman RM, Lamers SL, Weiner B, et al. Genome sequencing and analysis of geographically diverse clinical isolates of herpes simplex virus 2. J Virol 2015; 89:8219-8232.
38. Torrone E, Papp J, Weinstock H. Prevalence of Chlamydia trachomatis genital infection among persons aged 14-39 years - United States, 2007-2012. MMWR Morb Mortal Wkly Rep 2014; 63:834-838.
39. Heijne JC, Tao G, Kent CK, Low N. Uptake of regular chlamydia testing by U.S. women: a longitudinal study. Am J Prev Med 2010; 39:243-250.
40. Datta SD, Torrone E, Kruszon-Moran D, et al. Chlamydia trachomatis trends in the United States among persons 14 to 39 years of age, 1999-2008. Sex Transm Dis 2012; 39:92-96.
41. Price MJ, Ades AE, Soldan K, et al. The natural history of Chlamydia trachomatis infection in women: a multiparameter evidence synthesis. Health Technol Assess 2016; 20:1-250.
42. Batteiger BE, Xu F, Johnson RE, Rekart ML. Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. J Infect Dis 2010; 201:S178-S189.
43. Rank RG, Whittum-Hudson JA. Protective immunity to chlamydial genital infection: evidence from animal studies. J Infect Dis 2010; 201 (Suppl 2): S168-S177.
44. Geisler WM, Lensing SY, Press CG, Hook EW 3rd. Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection. J Infect Dis 2013; 207:1850-1856.
45. Li W, Murthy AK, Guentzel MN, et al. Antigen-specific CD4- T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection. J Immunol 2008; 180:3375-3382.
46. Stary G, Olive A, Radovic-Moreno AF, et al. VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science 2015; 348:aaa8205.
47. Olsen AW, Follmann F, Erneholm K, et al. Protection against Chlamydia trachomatis infection and upper genital tract pathological changes by vaccine- promoted neutralizing antibodies directed to the VD4 of the major outer membrane protein. J Infect Dis 2015; 212:978-989.
48. Finco O, Frigimelica E, Buricchi F, et al. Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proc Natl Acad Sci U S A 2011; 108:9969-9974.
49. Karunakaran KP, Yu H, Jiang X, et al. Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine. Vaccine 2015; 33:2159-2166.
50. Rinaudo CD, Telford JL, Rappuoli R, Seib KL. Vaccinology in the genome era. J Clin Invest 2011; 119:2515-2525.
51. Picard MD, Bodmer JL, Gierahn TM, et al. Resolution of Chlamydia trachomatis infection is associated with a distinct T cell response profile. Clin Vaccine Immunol 2015; 22:1206-1218.
52. Wang Y, Kahane S, Cutcliffe LT, et al. Development of a transformation system for Chlamydia trachomatis: restoration of glycogen biosynthesis by acquisition of a plasmid shuttle vector. PLoS Pathog 2011; 7:e1002258.
53. Yu H, Karunakaran KP, Jiang X, Brunham RC. Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis. Expert RevVaccines 2016; 15:977-988.
54. Boje S, Olsen AW, Erneholm K, et al. A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-gamma(-) CMI responses protects against a genital infection in minipigs. Immunol Cell Biol 2016; 94:185-195.
55. Kari L, Whitmire WM, Olivares-Zavaleta N, et al. A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. J Exp Med 2011; 208:2217-2223.
56. European Centre for Disease Prevention and Control. Sexually transmitted infections in Europe 1990-2010. Stockholm: ECDC; 2012. http://www.ecdc.europa.eu/en/publications/publications/201206-sexually-transmitted-infectionseurope-2010.pdf. [Accessed 22 November 2016]
57. Unemo M, Del Rio C, Shafer WM. Antimicrobial resistance expressed by Neisseria gonorrhoeae: a major global public health problem in the 21st century. Microbiol Spectr 2016; 4:.
58. Fifer H, Natarajan U, Jones L, et al. Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med 2016; 374:2504-2506.
59. Jerse AE, Bash MC, Russell MW. Vaccines against gonorrhea: current status and future challenges. Vaccine 2014; 32:1579-1587.
60. Edwards JL, Jennings MP, Apicella MA, Seib KL. Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development. Crit Rev Microbiol 2016; 42:928-941.
61. Wetzler LM, Feavers IM, Gray-Owen SD, et al. Abstract: and recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) workshop "Gonorrhea Vaccines: the Way Forward". Clin Vaccine Immunol 2016; 23:656-663.
62. Zielke RA, Wierzbicki IH, Baarda BI, et al. Proteomics-driven antigen discovery for development of vaccines against gonorrhea. Mol Cell Proteomics 2016; 15:2338-2355.
63. McClure R, Nudel K, Massari P, et al. The gonococcal transcriptome during infection of the lower genital tract in women. PLoS One 2015; 10:e0133982.
64. Petousis-Harris H, Paynter J, Morgan J, et al. Effectiveness of a group B OMV meningococcal vaccine on gonorrhea in New Zealand - a case control study. Abstract presented at: 20th International Pathogenic Neisseria Conference. Manchester, UK; 2016.
65. Lawn JE, Blencowe H, Waiswa P, et al. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet 2016; 387:587-603.
66. Read P, Fairley CK, Chow EP. Increasing trends of syphilis among men who have sex with men in high income countries. Sex Health 2015; 12:155-163.
67. World Health Organization. Global Health Sector Strategy on sexually transmitted infections, 2016-2021. 2016. http://www.who.int/reproductivehealth/ghs-strategies/en/. [Accessed 22 November 2016]
68. Taylor MM, Zhang X, Nurse-Findlay S, et al. The amount of penicillin needed to prevent mother-to-child transmission of syphilis. Bull World Health Organ 2016; 94:559-560.
69. Cameron CE, Lukehart SA. Current status of syphilis vaccine development: need, challenges, prospects. Vaccine 2014; 32:1602-1609.
70. Miller JN. Immunity in experimental syphilis. VI. Successful vaccination of rabbits with Treponema pallidum, Nichols strain, attenuated by g-irradiation. J Immunol 1973; 110:1206-1215.
71. Houston S, Taylor JS, Denchev Y, et al. Conservation of the host-interacting proteins Tp0750 and pallilysin among treponemes and restriction of proteolytic capacity to Treponema pallidum. Infect Immun 2015; 83:4204-4216.
72. Ke W, Molini BJ, Lukehart SA, Giacani L. Treponema pallidum subsp. pallidum TP0136 protein is heterogeneous among isolates and binds cellular and plasma fibronectin via its NH2-terminal end. PLoS Negl Trop Dis 2015; 9:e0003662.
73. Cejkova D, Strouhal M, Norris SJ, et al. A retrospective study on genetic heterogeneity within Treponema strains: subpopulations are genetically distinct in a limited number of positions. PLoS Negl Trop Dis 2015; 9:e0004110.
74. Lithgow KV, Cameron CE. Vaccine development for syphilis. Expert Rev Vaccines 2016. [Epub ahead of print] This review summarizes the key strategies for developing a vaccine against syphilis.
75. Menon S, Stansfield SH, Walsh M, et al. Sero-epidemiological assessment of Chlamydia trachomatis infection and sub-fertility in Samoan women. BMC Infect Dis 2016; 16:175.
76. Press release: The Bill & Melinda Gates Foundation to fund disease surveillance network in Africa and Asia to prevent childhood mortality and help prepare for the next epidemic; 2015. http://www.gatesfoundation.org/Media-Center/Press-Releases/2015/05/Child-Health-and-Mortality-Prevention-Surveillance-Network. [Accessed 22 November 2016]
77. Alsallaq RA, Schiffer JT, Longini IM Jr, et al. Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2. Sex Transm Dis 2010; 37:290-297.
78. Freeman EE, White RG, Bakker R, et al. Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine 2009; 27:940-946.
79. Owusu-Edusei K Jr, Chesson HW, Gift TL, et al. Cost-effectiveness of chlamydia vaccination programs for young women. Emerg Infect Dis 2015; 21:960-968.
80. Knipe DM, Corey L, Cohen JI, Deal CD. Abstract: and recommendations from a National Institute of Allergy and Infectious Diseases (NIAID) workshop on "Next Generation Herpes Simplex Virus Vaccines". Vaccine 2014; 32:1561-1562.
81. Hobbs MM, Sparling PF, Cohen MS, et al. Experimental gonococcal infection in male volunteers: cumula tive experience with Neisseria gonorrhoeae strains FA1090 and MS11mkC. Front Microbiol 2011; 2:123.
82. World Health Organization. WHO preferred product characteristics; 2014. http://www.who.int/immunization/research/vaccine-preferred-product-charac teristics/en/. [Accessed 22 November 2016]
83. Bishai DM, Champion C, Steele ME, Thompson L. Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa. Health Aff (Millwood) 2011; 30:1058-1064.
84. Rees H, Holmes K. The STI vaccine roadmap - a long overdue intervention. Vaccine 2014; 32:1638-1639